Lyell Immunopharma, Inc. financial data

Symbol
LYEL on Nasdaq
Location
South San Francisco, CA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 12 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 793% % -49%
Debt-to-equity 27% % 77%
Return On Equity -97% % -179%
Return On Assets -76% % -153%
Operating Margin -836359% % -143%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 21,218,217 shares -92%
Common Stock, Shares, Outstanding 19,293,951 shares -92%
Entity Public Float $306,000,000 USD -53%
Common Stock, Value, Issued $2,000 USD -92%
Weighted Average Number of Shares Outstanding, Basic 18,268,000 shares 43%
Weighted Average Number of Shares Outstanding, Diluted 18,268,000 shares 43%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $41,000 USD -35%
Research and Development Expense $28,172,000 USD -29%
General and Administrative Expense $49,041,000 USD -3.2%
Operating Income (Loss) $342,907,000 USD -58%
Nonoperating Income (Expense) $17,247,000 USD 31%
Net Income (Loss) Attributable to Parent $325,660,000 USD -60%
Earnings Per Share, Basic 0 USD/shares 39%
Earnings Per Share, Diluted 0 USD/shares 39%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $123,575,000 USD 23%
Marketable Securities, Current $196,049,000 USD -42%
Assets, Current $328,201,000 USD -27%
Property, Plant and Equipment, Net $36,722,000 USD -58%
Operating Lease, Right-of-Use Asset $19,912,000 USD -46%
Other Assets, Noncurrent $2,545,000 USD -50%
Assets $407,965,000 USD -34%
Accounts Payable, Current $2,568,000 USD -29%
Liabilities, Current $31,878,000 USD -4.9%
Operating Lease, Liability, Noncurrent $44,285,000 USD -14%
Other Liabilities, Noncurrent $2,681,000 USD -25%
Liabilities $78,844,000 USD -11%
Accumulated Other Comprehensive Income (Loss), Net of Tax $201,000 USD -74%
Retained Earnings (Accumulated Deficit) $1,478,831,000 USD -28%
Stockholders' Equity Attributable to Parent $329,121,000 USD -38%
Liabilities and Equity $407,965,000 USD -34%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $54,738,000 USD -30%
Net Cash Provided by (Used in) Financing Activities $27,000 USD
Net Cash Provided by (Used in) Investing Activities $69,466,000 USD 216%
Common Stock, Shares Authorized 500,000,000 shares 0%
Common Stock, Shares, Issued 19,294,000 shares -92%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $14,729,000 USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $125,160,000 USD 24%
Deferred Tax Assets, Valuation Allowance $359,440,000 USD 45%
Deferred Tax Assets, Gross $366,357,000 USD 39%
Operating Lease, Liability $53,073,000 USD -9.4%
Payments to Acquire Property, Plant, and Equipment $246,000 USD 720%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $326,219,000 USD -61%
Lessee, Operating Lease, Liability, to be Paid $65,059,000 USD -13%
Property, Plant and Equipment, Gross $118,879,000 USD -23%
Operating Lease, Liability, Current $8,788,000 USD 23%
Lessee, Operating Lease, Liability, to be Paid, Year Two $13,341,000 USD 9.3%
Lessee, Operating Lease, Liability, to be Paid, Year One $12,959,000 USD 9.3%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $11,986,000 USD -27%
Lessee, Operating Lease, Liability, to be Paid, Year Three $13,005,000 USD 3.5%
Deferred Tax Assets, Operating Loss Carryforwards $176,298,000 USD 32%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $3,659,000 USD 815%
Lessee, Operating Lease, Liability, to be Paid, Year Four $10,398,000 USD -20%
Additional Paid in Capital $1,807,749,000 USD 7.4%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization $3,441,000 USD -32%
Deferred Tax Assets, Net of Valuation Allowance $6,917,000 USD -54%
Share-based Payment Arrangement, Expense $24,343,000 USD -27%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%